That guy writes dozens of articles per year, often
Post# of 148187
(Total Views: 387)
Posted On: 09/26/2019 4:04:13 AM
That guy writes dozens of articles per year, often pretty generic ones, and then pumps a few of the tickers he covered on Stocktwits and iHub. That's my observation: When a position goes against him, he disappears or turns around 180° (recent examples: Marker and CytoDyn). When someone states where he is wrong, his incredible arrogance can't stand it, because he thinks he is the best biotech analyst in the world, though his track record is ****. Good thing he is bearish now on CYDY, since he is, like most SA authors, an excellent contra indicator...
Yes, leronlimab is the way to go for HIV patients and has the potentual to be one of the most important molecules of the 21st century. The efficacy and safety profile is just off the charts. That's why we are all here. Now, please get the financing and BLA done to release that potential, patients and investors are eagerly waiting for it.
Yes, leronlimab is the way to go for HIV patients and has the potentual to be one of the most important molecules of the 21st century. The efficacy and safety profile is just off the charts. That's why we are all here. Now, please get the financing and BLA done to release that potential, patients and investors are eagerly waiting for it.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼